Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Supplement Review Timeline Hinges On Need For Inspection

Executive Summary

FDA notes that it may not be evident right away whether an inspection will be required as part of the review.

Advertisement

Related Content

FDA Outlines Criteria For Approving Manufacturing Supplements Under GDUFA
Foreign Regulator Training Only Provides Short-Term Gains, FDA Official Says
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Topics

Advertisement
UsernamePublicRestriction

Register

PS056265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel